Dale J. Kempf

12.7k total citations · 2 hit papers
146 papers, 8.8k citations indexed

About

Dale J. Kempf is a scholar working on Infectious Diseases, Virology and Organic Chemistry. According to data from OpenAlex, Dale J. Kempf has authored 146 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Infectious Diseases, 74 papers in Virology and 56 papers in Organic Chemistry. Recurrent topics in Dale J. Kempf's work include HIV/AIDS drug development and treatment (106 papers), HIV Research and Treatment (74 papers) and Hepatitis C virus research (29 papers). Dale J. Kempf is often cited by papers focused on HIV/AIDS drug development and treatment (106 papers), HIV Research and Treatment (74 papers) and Hepatitis C virus research (29 papers). Dale J. Kempf collaborates with scholars based in United States, United Kingdom and Australia. Dale J. Kempf's co-authors include Daniel W. Norbeck, Akhteruzzaman Molla, Sudthida Vasavanonda, Martin King, Eugene Sun, Hing L. Sham, Norman E. Wideburg, Kennan C. Marsh, Scott C. Brun and John W. Erickson and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Dale J. Kempf

146 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1996 601 citations Akhteruzzaman Molla, Marina Korneyeva et al. Nature Medicine profile →
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

2008 514 citations Barry Bernstein, George J. Hanna et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dale J. Kempf United States	50	5.9k	5.0k	1.9k	1.7k	1.3k	146	8.8k
William A. Schleif United States	36	6.5k 1.1×	6.7k 1.3×	2.5k 1.3×	1.6k 1.0×	1.3k 1.0×	92	9.4k
Celia A. Schiffer United States	54	4.1k 0.7×	3.4k 0.7×	3.8k 2.0×	786 0.5×	1.2k 0.9×	214	8.2k
Tomáš Cihlář United States	51	7.8k 1.3×	2.6k 0.5×	2.2k 1.2×	674 0.4×	2.8k 2.1×	143	11.3k
Daria J. Hazuda United States	59	7.0k 1.2×	7.4k 1.5×	5.5k 2.8×	1.2k 0.7×	2.2k 1.7×	189	13.7k
John W. Erickson United States	44	3.7k 0.6×	3.1k 0.6×	3.6k 1.9×	1.0k 0.6×	824 0.6×	117	8.2k
Adrian S. Ray United States	44	4.4k 0.7×	1.7k 0.3×	1.6k 0.8×	467 0.3×	2.0k 1.5×	110	7.3k
Stefan G. Sarafianos United States	55	6.2k 1.1×	5.1k 1.0×	3.5k 1.8×	618 0.4×	1.8k 1.4×	197	9.0k
Rudi Pauwels Belgium	63	9.2k 1.6×	8.1k 1.6×	4.4k 2.3×	2.8k 1.7×	3.4k 2.7×	145	14.9k
Karen S. Anderson United States	52	3.6k 0.6×	2.7k 0.5×	5.2k 2.7×	1.2k 0.7×	1.3k 1.0×	241	9.7k
Daniel W. Norbeck United States	30	2.9k 0.5×	2.5k 0.5×	1.2k 0.6×	1.4k 0.8×	484 0.4×	62	4.5k

Countries citing papers authored by Dale J. Kempf

Since Specialization

Citations

This map shows the geographic impact of Dale J. Kempf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dale J. Kempf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dale J. Kempf more than expected).

Fields of papers citing papers by Dale J. Kempf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dale J. Kempf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dale J. Kempf. The network helps show where Dale J. Kempf may publish in the future.

Co-authorship network of co-authors of Dale J. Kempf

This figure shows the co-authorship network connecting the top 25 collaborators of Dale J. Kempf. A scholar is included among the top collaborators of Dale J. Kempf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dale J. Kempf. Dale J. Kempf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hübner, Marc P., Marianne Koschel, Stefan J. Frohberger, et al.. (2019). In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae. PLoS neglected tropical diseases. 13(8). e0007636–e0007636. 23 indexed citations

Kempf, Dale J., Cheri E. Klein, Hui-Ju Chen, et al.. (2007). Pharmacokinetic Enhancement of the Hepatitis C Virus Protease Inhibitors VX-950 and SCH 503034 by Co-Dosing with Ritonavir. Antiviral chemistry & chemotherapy. 18(3). 163–167. 33 indexed citations

Masse, Sherie, Xiaozhi Lu, Tatyana Dekhtyar, et al.. (2007). In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir. Antimicrobial Agents and Chemotherapy. 51(9). 3075–3080. 25 indexed citations

Larson, Daniel P., Rolf Wagner, Todd W. Rockway, et al.. (2007). Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(2). 568–570. 16 indexed citations

DeGoey, David A., David J. Grampovnik, Larry L. Klein, et al.. (2006). Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV. Bioorganic & Medicinal Chemistry. 14(19). 6695–6712. 24 indexed citations

Hickman, Dean, Sudthida Vasavanonda, Warren M. Kati, et al.. (2004). Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir. Antimicrobial Agents and Chemotherapy. 48(8). 2911–2917. 24 indexed citations

Sáez‐Llorens, Xavier, Richard A. Rode, Perry Gomez, et al.. (2003). Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. The Pediatric Infectious Disease Journal. 22(3). 216–223. 102 indexed citations

Sáez‐Llorens, Xavier, Richard A. Rode, Edward Handelsman, et al.. (2003). . The Pediatric Infectious Disease Journal. 22(3). 216–223. 5 indexed citations

Sham, Hing L., David A. Betebenner, Xiaoqi Chen, et al.. (2002). Synthesis and structure–activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir). Bioorganic & Medicinal Chemistry Letters. 12(8). 1185–1187. 14 indexed citations

10.

Benson, Constance A., Steven G. Deeks, Scott C. Brun, et al.. (2002). Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced Patients. The Journal of Infectious Diseases. 185(5). 599–607. 119 indexed citations

11.

Sham, Hing L., Chen Zhao, Leping Li, et al.. (2002). Novel lopinavir analogues incorporating non-Aromatic P-1 side chains—Synthesis and structure–Activity relationships. Bioorganic & Medicinal Chemistry Letters. 12(21). 3101–3103. 41 indexed citations

12.

Molla, Akhteruzzaman, Sudthida Vasavanonda, Gondi Kumar, et al.. (1998). Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus. Virology. 250(2). 255–262. 154 indexed citations

13.

Kempf, Dale J., Akhteruzzaman Molla, Kennan C. Marsh, et al.. (1997). Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease. Bioorganic & Medicinal Chemistry Letters. 7(6). 699–704. 4 indexed citations

14.

Molla, Akhteruzzaman, Marina Korneyeva, Qing Gao, et al.. (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine. 2(7). 760–766. 601 indexed citations breakdown →

15.

Markowitz, Martin, Hongmei Mo, Dale J. Kempf, et al.. (1995). Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. Journal of Virology. 69(2). 701–706. 189 indexed citations

16.

Kageyama, Seiji, Eiji Kojima, Takuma Shirasaka, et al.. (1994). A C ₂ Symmetry-Based HIV Protease Inhibitor, A77003, Irreversibly Inhibits Infectivity of HIV-1 In Vitro. AIDS Research and Human Retroviruses. 10(6). 735–743. 22 indexed citations

17.

Ho, David D., Hongmei Mo, Dale J. Kempf, et al.. (1994). Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. Journal of Virology. 68(3). 2016–2020. 192 indexed citations

18.

Kempf, Dale J., W E Kohlbrenner, Norman E. Wideburg, et al.. (1993). Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. Journal of Medicinal Chemistry. 36(3). 320–330. 107 indexed citations

19.

Rosenberg, Saul H., Joseph F. Dellaria, Dale J. Kempf, et al.. (1990). Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site. Journal of Medicinal Chemistry. 33(6). 1582–1590. 17 indexed citations

20.

Kempf, Dale J., et al.. (1987). Renin inhibitors based on novel dipeptide analogs. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond. Journal of Medicinal Chemistry. 30(11). 1978–1983. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact